Organon & Co. (NYSE:OGN) Hits New 12-Month High – Still a Buy?

Organon & Co. (NYSE:OGN)’s stock price hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $13.79 and last traded at $13.7750, with a volume of 2207764 shares trading hands. The stock had previously closed at $13.74.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Organon & Co. currently has an average rating of “Reduce” and an average target price of $11.40.

Organon & Co. Price Performance

The company has a debt-to-equity ratio of 8.43, a quick ratio of 1.44 and a current ratio of 1.95. The business has a 50 day moving average price of $13.70 and a 200-day moving average price of $12.38. The company has a market capitalization of $3.62 billion, a price-to-earnings ratio of 17.89, a P/E/G ratio of 1.27 and a beta of 1.55.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Stockholders of record on Friday, August 14th were given a dividend of $0.02 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is 10.39%.

Institutional Investors Weigh In On Organon & Co.

A number of large investors have recently bought and sold shares of the stock. Allied Private Wealth LLC acquired a new position in shares of Organon & Co. during the second quarter valued at about $33,000. WNY Asset Management LLC acquired a new stake in shares of Organon & Co. in the 1st quarter valued at about $64,000. Wealth Effects LLC bought a new stake in Organon & Co. in the 1st quarter valued at about $75,000. Nykredit A S acquired a new position in Organon & Co. during the 2nd quarter worth approximately $76,000. Finally, GAMMA Investing LLC boosted its holdings in Organon & Co. by 69.8% in the second quarter. GAMMA Investing LLC now owns 5,782 shares of the company’s stock worth $78,000 after acquiring an additional 2,376 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Company Profile

Organon & Co is a global healthcare company focused primarily on women’s health, biosimilars and a portfolio of established medicines. The company develops, manufactures and commercializes prescription products designed to address a range of health needs, with an emphasis on expanding access to treatments in markets around the world.

Its women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines used in areas including fertility and reproductive health.